TuHURA Biosciences HURA 深 滬
等待開盤 10-28 09:30:00 美东时间
2.11
+0.070
+3.43%
華盛通- 最 高2.12
- 今 開2.05
- 成交量 40.12万股
- 最 低 1.99
- 昨 收 2.04
- 總市值 1.34亿
- 52周最高 3.43
- 市盈率 靜 --
- 換手率 0.63%
- 52周最低 0.41
- 委 比 -90.70%
- 總股本 6372.66万
- 歷史最高 190225.00
- 量 比 0.59
- 振 幅 6.37%
- 歷史最低 0.41
- 每 手 1
- 風險率 0.60%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多美股大行评级 | 潜在涨幅94.81%！富瑞上调ArriVent BioPharma(AVBP)目标价至30美元，维持"买入"评级
今日重点评级关注：富瑞：维持ArriVent BioPharma"买入"评级，目标价从18美元升至30美元；古根海姆：维持第一太阳能"买入"评级，目标价从282美元升至299美元
今天 12:30
TuHURA Reports Initial Data Showing Partial Responses In First Three Metastatic Merkel Cell Carcinoma Patients Treated With Ifx-2.0 Plus Keytruda
Preliminary results demonstrate major objective tumor responses in first 3 patients at 6 months Company to host a webcast today, October 26, 2026, at 8:30 am ET TAMPA, Fla., Oct. 26, 2026 /PRNewswire/ -- TuHURA Biosciences, Inc. (NASDAQ:HURA) ("TuHURA" or the "Company"), a Phase 3 immuno-oncology c...
10-26 19:35
TuHURA Biosciences Adds Borrowing Under Credit Facility
The latest announcement is out from TuHURA Biosciences ( ($HURA) ). On April 21...
10-17 05:30
TuHURA Biosciences Secures US Patent For TBS-2025, Entitled ‘Anti-VISTA Antibodies And Uses Thereof’
Patent extends coverage to include bispecific/multi-specific antibodies across all classes of human antibodies TAMPA, Fla., Oct. 13, 2026 /PRNewswire/ -- TuHURA Biosciences, Inc. (NASDAQ:HURA) ("TuHURA" or the "Company"), a Phase 3 immuno-oncology company developing novel therapeutics to overcome re...
10-13 19:48
TuHURA Biosciences Receives U.S. Patent For Administration Of DOR Antagonists
TuHURA Biosciences, Inc. (NASDAQ:HURA) (“TuHURA” or the “Company”), a Phase 3 immuno-oncology company developing novel therapeutics to overcome resistance to cancer immunotherapy, today announced that the United States Patent and Trademark Office has issued U.S. Patent No. 12,734,168 entitled, “Delt...
10-05 19:48
TuHURA Biosciences Draws Additional Funds From Credit Facility
TuHURA Biosciences ( ($HURA) ) just unveiled an announcement. TuHURA Bioscience...
09-25 05:30
TuHURA Biosciences Adopts 2026 Inducement Equity Plan
The latest update is out from TuHURA Biosciences ( ($HURA) ). On September 10, ...
09-17 05:30
TuHURA Biosciences to Present at the H.C. Wainwright 28th Annual Global Investment Conference
TAMPA, Fla., Sept. 8, 2026 /PRNewswire/ -- TuHURA Biosciences, Inc. (NASDAQ:HURA) ("TuHURA" or the "Company"), a Phase 3 immuno-oncology company developing novel therapeutics to overcome res...
09-08 19:45
TuHURA Biosciences draws additional funds from credit facility
TuHURA Biosciences ( ($HURA) ) has shared an update. TuHURA Biosciences, Inc. p...
09-05 05:51
Parabilis Medicines Appoints Accomplished Drug Development Leader Craig L. Tendler, M.D., to Board of Directors
Parabilis Medicines announced the appointment of Craig L. Tendler, M.D., to its Board of Directors. Dr. Tendler, a seasoned oncology expert with over 30 years of experience at Johnson & Johnson, will also continue his role as a scientific advisor. His extensive background in clinical development and regulatory approvals is expected to significantly benefit Parabilis as it advances its lead drug, zolucatetide, and expands its pipeline of innovativ...
08-25 11:00
